Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Darfen 400 vs Nurofen Forte Express in Healthy Volunteers
NCT05663398Phase 1Completed
- Sponsor
- Darnitsa
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen in pain, fever and inflammation (2 arms), sponsored by Darnitsa. Primary endpoints: Maximum plasma concentration at 24 hours and Area under the concentration-time curve from time zero to the last quantifiable concentration at 24 hours. Started May 2022; status: completed.
02
Drugs
ibuprofen
03
Conditions
painfeverinflammation
Beyond the preview
Go deeper on NCT05663398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663398.